Researchers Develop New Animal Model of Multiple Myeloma
Researchers in the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed a new animal model of multiple myeloma,…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Potential Therapeutic Target for Drug-resistant Multiple Myelomas Identified in Study
A subunit of a signaling protein may be a new therapeutic target in multiple myeloma (MM), a hematologic malignancy with high relapse rates and resulting drug resistance in patients, according…
New Adjuvant Therapy Shows Promising Results to Treat Multiple Myeloma, B-Cell Malignancies
A new class of drugs that activate a protein in cells’ endoplasmic reticulum may be used as an adjuvant therapy to treat B-cell malignancies, according to the…
Disrupting Specific Protein May Be Effective Multiple Myeloma Treatment Strategy
Researchers at Buffalo, New York-based Roswell Park Cancer Institute revealed that knocking down individual RabGTPases (Rab) proteins in myeloma cells was sufficient to disrupt the trafficking of…
Protein Identified that May Point to Myeloma Patients Likely to Respond to Proteasome Inhibitors
Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with other institutions, identified a gene called TJP1 that could help predict which…
Takeda Publishes Promising Trial Results on Ixazomib, an Approved Drug to Treat Relapsed Multiple Myeloma
Takeda Pharmaceutical has published promising data from the TOURMALINE-MM1 Phase 3 clinical trial of patients with relapsed and/or refractory multiple myeloma (MM), treated with the combination…
